September 01, 2020
Gilead unit Kite Pharma is asking the Federal Circuit to wipe out a $1.2 billion judgment in Juno Therapeutics Inc.'s favor in a patent case over Kite's cancer treatment Yescarta, saying the judgment "reward[s] Juno for Kite's success in solving the very problems Juno could not."